Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

  • Revenue in CHF (TTM)45.17bn
  • Net income in CHF6.47bn
  • Incorporated1996
  • Employees110.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVN:VTX since
announced
Transaction
value
Vedere Bio IncDeal completed30 Sep 202030 Sep 2020Deal completed-0.05%280.00m
Amblyotech IncDeal completed20 Apr 202020 Apr 2020Deal completed-6.44%--
Data delayed at least 15 minutes, as of Nov 24 2020 15:29 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bayer AG45.56bn-17.28bn49.26bn100.62k--1.45--1.08-16.27-9.5542.9431.890.3371.953.83406,023.70-12.773.25-16.994.1051.7460.77-37.897.560.80715.490.579982.9118.521.0575.47-6.232.254.81
Takeda Pharmaceutical Co Ltd28.12bn489.26m49.88bn47.50k101.651.229.881.7735.6635.662,055.362,982.300.25471.284.2067,834,590.000.44311.630.51082.0768.4868.861.745.281.081.570.5126164.4456.9313.11-67.28--14.900.00
Chugai Pharmaceutical Co Ltd6.58bn1.77bn67.05bn7.39k37.158.13--10.19123.15123.15458.27562.880.69761.523.57101,954,700.0018.7510.3422.5312.2564.8154.4526.8715.803.05529.710.0049.7618.358.2770.3625.3226.1323.87
Novartis AG45.17bn6.47bn195.14bn110.00k28.123.6316.454.322.812.8119.6321.820.40372.166.24434,648.505.786.227.667.6971.1768.3014.3217.320.6859--0.411781.915.67-1.94-44.19-7.69-7.893.11
Roche Holding AG60.28bn12.96bn263.86bn97.74k20.428.2914.594.3814.9714.9769.6536.870.75092.495.15616,749.4017.0313.6125.2220.3272.3670.9922.6819.480.931126.720.301771.338.135.3128.977.667.992.38
Data as of Nov 24 2020. Currency figures normalised to Novartis AG's reporting currency: Swiss Franc CHF

Institutional shareholders

15.21%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Oct 202066.70m2.70%
Norges Bank Investment Managementas of 31 Dec 201954.26m2.20%
UBS Asset Management Switzerland AGas of 31 Dec 201952.85m2.14%
Wellington Management Co. LLPas of 06 Nov 202043.60m1.77%
Capital Research & Management Co. (Global Investors)as of 30 Sep 202037.85m1.53%
Credit Suisse Asset Management (Schweiz) AGas of 30 Oct 202031.24m1.27%
BlackRock Fund Advisorsas of 05 Nov 202030.61m1.24%
Capital Research & Management Co. (World Investors)as of 30 Sep 202022.11m0.90%
Z�rcher Kantonalbank (Investment Management)as of 30 Sep 202022.00m0.89%
Magellan Asset Management Ltd.as of 30 Sep 202014.12m0.57%
More ▼
Data from 31 Dec 2019 - 31 Oct 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.